about
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesRecognition of an epitope of a breast cancer antigen by human antibody.Using protein microarray as a diagnostic assay for non-small cell lung cancerDiscovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system.Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.Immunologic approaches to antigen discovery for cancer vaccines.Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.Therapeutic vaccination with tumor cells that engage CD137.Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.ErbB2 immune response in breast cancer patients with soluble receptor ectodomain.Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.Therapeutic potential of dendritic-based vaccines.Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.Tumor antigens discovery: perspectives for cancer therapy.p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.Serum autoantibodies as biomarkers for early cancer detection.Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers.Active Immunotherapy of Cancer.Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.Mutated Ras peptides as vaccines in immunotherapy of cancer.New paths in human cancer serology.Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.Gene and cell transfer for specific immunotherapy.Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer.Prostate cancer health disparities: An immuno-biological perspective.
P2860
Q24804837-578048BE-B4A2-48FD-88D7-04F097A1871DQ30714875-438E7E05-B3AF-47EB-ABB3-C7FA21228C7FQ30796772-18D6179F-E640-4FA3-995F-AE3117B09ADDQ31048160-26E2A339-05D7-4A49-AD32-B1A05C96C96BQ31116916-3FB0EBA4-F1FE-4F27-A108-8D2D8A7712CCQ33686433-9C6DDA3A-E257-492F-9CAA-372DB77786A3Q34074742-372966A6-5804-47DF-AEF2-2CE4556672A4Q34734310-326DA298-09A9-4C7A-9D4C-AB18186149A2Q35059164-D31DBD0A-7ACE-4946-94D6-5A565EEF242FQ35071688-74D8D88D-9389-4431-9A04-141137E604FCQ35403688-177D1D59-870B-4914-8EA9-7CB24061515AQ35583352-F7137617-F248-4BFE-A446-A557F5A70CD8Q35693584-88342777-60EF-48EB-A5F9-8AF2428932E1Q35809954-8BB98ACE-52FD-4AD7-8075-772BA21F4248Q35872183-2EEF2E76-32E0-4092-A116-90587FCDF090Q36181313-7344CC70-931A-41CD-8D84-35C3A42FE122Q36369960-B03EBB8E-EC06-4DB8-842B-411AEEDE4B21Q36400634-C6F7007C-CDF2-4215-B278-C703014C1437Q36438078-47835C96-ABC9-4EBF-A476-6C4278860578Q36622181-4CFD7E6D-8C87-4B90-B4ED-C05903F63EC0Q36840281-13B3B506-C5D2-4381-8207-D2245C2ABD79Q37049451-02A71DE2-10A9-4814-9AB7-B377BE69F1FFQ37252915-18B7E4B6-3D01-4CF2-8C15-F0E499DA19A8Q37266210-97B9335B-A92D-42E4-81BF-617E37C81041Q37622471-38563960-2905-4F89-9035-FD1ED10B6C11Q38310231-F55CFFA0-FE50-4CBA-A265-32CCCA01226BQ38635419-8B5DE4E2-75F9-4F36-906B-86DFFD7384C3Q39516809-D48E958F-FF21-429A-BB1C-B63CE02903F6Q39740168-EF28877E-B7B3-4677-AE81-C41DC194681BQ40766832-2712A477-2B46-415A-A1AE-859FADC13283Q40846439-A8525697-40C4-41A3-8BBB-FE99D54CC954Q41821668-C5C3728C-8C80-42E0-A97B-1BF82D19C453Q45884692-6A29E8F0-B85F-4446-A5E2-C44E4583A559Q45888812-C6E2CE09-7986-45C1-B6F9-901F0A4FB2EDQ45895308-159CB4DB-8A50-4628-B713-DA21CD6FC469Q46537204-A487058A-56A4-4F99-A71D-0FFE59ECAA05
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Immunity to oncogenic proteins.
@en
type
label
Immunity to oncogenic proteins.
@en
prefLabel
Immunity to oncogenic proteins.
@en
P2093
P2860
P1476
Immunity to oncogenic proteins.
@en
P2093
Bernhard H
Cheever MA
Takahashi M
P2860
P356
10.1111/J.1600-065X.1995.TB00076.X
P577
1995-06-01T00:00:00Z